In this white paper, we discuss the challenges and opportunities associated with nucleic acid encapsulation technologies with a particular focus on mRNA encapsulation. We also share some of our insights into the key requirements for our LNP toolbox and how this approach facilitates a low-risk transition from pre-clinical stages to cGMP production.
You may also be interested in:
mRNA
Clinical Supply Services
Commercial Supply Services
Manufacturing: GMP Drug Substance
Author(s):
Alexander Schwenger, Ph.D.
Head of Process Development - LNP
Telmo Graça, Ph.D.
Process and Technology Lead - mRNA
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center
e-book
Experts in Expression: Recent Advances in CHO Upstream Bioproduction
Constantly evolving biopharmaceutical pipelines require continuous evolution of CHO-based...
Article
Powering the Development of Tomorrow’s Bispecific Antibodies
bYlok® technology is changing the way bispecific antibodies are designed. Achieving the correct...
Webinar (on-demand)
Tech Transfer Strategies and Best Practices to Optimize Your Clinical and Commercial Supply
Tech Transfers for biological products, whether they occur from a pharma company, another CMO, or a...
White paper
Exploring Technologies for cGMP Success with Encapsulation of Nucleic Acid-based Therapeutics
In this white paper, we discuss the challenges and opportunities associated with nucleic acid...
Presentation (slides)
From Lab to Large-Scale Process Validation: Mastering Regulatory Requirements
Start with the end in mind: Meticulous planning of CMC activities is a cornerstone of success to...
White paper
Mastering Biologics Tech Transfers: Key Success Factors
Tech transfers play a vital role in ensuring that medicines reach patients on time. This article...
mAb
Article
Creating Next-Generation CHO Expression Platforms Through Application of Omics Technologies
Chinese hamster ovary (CHO)-based biomanufacturing platforms have transformed the industrial...
microbial yeast cells - blue
R&D Blog post
Leveraging the potential of XS® Pichia Expression System
One of the most important goals of genetic engineering, especially within the biopharmaceutical...
White paper
An Integrated End-to-End Approach to Antibody Drug Conjugate Development and Manufacturing
Antibody drug conjugates (ADCs) are revolutionizing cancer therapy with their highly specific...
man working with microscope in lab,Process Development,Biologics_Slough_18,,lab in slough,tech working in lab with computer,male tech pipetting,tech holding vial,tech working,Cell Iine process development,biologics lab worker, ,Biologics_Slough_29,Biologics , Biologics Slough
Webinar (on-demand)
Innovative Solutions for Enhancing Biotherapeutic Expression and Development
The range of molecular formats being explored in drug discovery and development has expanded far...
man working with microscope in lab,Process Development,Biologics_Slough_18,,lab in slough,tech working in lab with computer,male tech pipetting,tech holding vial,tech working,Cell Iine process development,biologics lab worker, ,Biologics_Slough_29,Biologics , Biologics Slough
Article
Accelerating the Path to Clinical Filing Applications with Rapid Toxicology Material Delivery
The application for investigational new drug (IND) and Clinical Trial Application (CTA) is a key...
mAb
Article
Rapid Delivery of Toxicological Material
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the...